WaferGen Biosystems, Inc. (OTC BB: WGBS) is focused on developing, manufacturing and commercializing next-generation systems for gene expression, genotyping, stem cell research and cell biology for the life science and pharmaceutical industries. The company is developing what could become the platform of choice for genetic analysis as well as cell monitoring enabling genomics and cell biology from research to clinic. WaferGen’s innovative systems are the first of their kind, providing researchers with critical performance advantages that are not available with existing technologies. For further information, visit the Company’s web site at www.wafergen.com.
- 17 years ago
QualityStocks
WaferGen Biosystems, Inc. (OTC BB: WGBS)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – C3is Inc. (NASDAQ: CISS) Closes Approximately $9 Million Public Offering
C3is (NASDAQ: CISS), a ship-owning company providing dry bulk and tanker seaborne transportation services, announced the closing…
-
Antisense’s Moment: How Rational Design Is Rewriting Drug Development Economics
Industry data shows small molecules achieve 5–10% approval rates over 15–20 years; antisense oligonucleotides (“ASOs”)…
-
Xeriant Inc. (XERI) Is ‘One to Watch’
Xeriant offers diversified exposure to next-generation aerospace, advanced materials, and sustainability-focused technologies through its strategic…